

MD Anderson at the 2024 ASH Annual Meeting



MDAnderson.org/ASH



Saturday, Dec. 7 **As of Nov. 15**

9:30-10:45 a.m.	AML M&Ms: How to Integrate Mutations and MRD Data	Seaport Ballroom ABCD (Manchester Grand Hyatt San Diego)
	Chair	
	Incorporating Mutational Data and MRD Assessments into Treatment Decisions for Transplant-Ineligible Patients	Courtney DiNardo, M.D.
9:30-11:00 a.m.	604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms—Determinants of Venetoclax Resistance and Response	Grand Hall B (Manchester Grand Hyatt San Diego)
9:45-10:00 a.m.	Abstract 50: A Single-Cell T-Cell Reference Map Delineates the Biological Landscape of CD4+ T Cells in Myelodysplastic Syndromes Under Venetoclax Therapy	Juan Jose Rodriguez Sevilla, M.D., Ph.D.
9:30-11:00 a.m.	617. Acute Myeloid Leukemias: Commercially Available Therapies—How Do We Start? Upfront Regimens with Commercially Available Therapies	Hall B (San Diego Convention Center)
9:45-10:00 a.m.	Abstract 56: Phase II Study of Cladribine with Low Dose Cytarabine and Venetoclax Alternating with Azacytidine and Venetoclax for Newly Diagnosed Acute Myeloid Leukemia	Alexandre Bazinet, M.D.
9:30-11:00 a.m.	618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis—Multi-omic Applications for Disease Evolution and Response to Therapy	Seaport Ballroom EFGH (Manchester Grand Hyatt San Diego)
9:30-9:45 a.m.	Abstract 61: Single-Cell Multiomics Unveils Venetoclax-Resistant Monocytic Differentiation and Immune Evasion in <i>TP53</i> Mutant AML Clones	Edward Ayoub, Ph.D.
11:15 a.m.-12:15 p.m.	Career Development Lunch	Coronado Ballroom (Manchester Grand Hyatt San Diego)
	Medical Educators in Hematology	Tapan Kadia, M.D.
Noon-1:30 p.m.	802. Chemical Biology and Experimental Therapeutics: Novel Therapeutic Strategies for Hematologic Disorders—From Mechanistic to Preclinical Studies	Room 33 (San Diego Convention Center)
12:30-12:45 p.m.	Abstract 153: Pharmacological Targeting of the Heme-Regulated Inhibitor Kinase Overcomes Ineffective Erythropoiesis in Patients with Myelodysplastic Syndromes with Ringed Sideroblasts and Sickle Cell Disease	Vera Adema, Ph.D.
1:30-2:00 p.m.	Global Hematology Collaboration: Advancing Diversity and Leadership in Clinical Research	Sails Pavilion - ASH Health Equity Studio (San Diego Convention Center)
	Luis Enrique Malpica Castillo, M.D.	
2:00-3:15 p.m.	Chasing Zebras: Navigating Rare Myeloid Neoplasms	Grand Hall C (Manchester Grand Hyatt San Diego)
	Chair	
	BPDCN State of the Art	Naveen Pemmaraju, M.D.

2:00-3:30 p.m.	604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms—Novel Approaches to Targeting Epigenetics, Apoptosis and Immune Effectors in Myeloid Malignancies	Grand Hall B (Manchester Grand Hyatt San Diego)
2:30-2:45 p.m.	Abstract 207: Enhancing Macrophage Mediated Phagocytosis in AML: The Complementary Mechanisms of Venetoclax and Azacitidine Combination Therapy	Zhe Wang, M.D.
2:45-3:00 p.m.	Abstract 208: CBX250 Is a Novel Cathepsin G Peptide-HLA-Targeting T Cell Engager That Exhibits High Tumor Antigen Selectivity and Potent Antileukemic Activity In Vivo	Benjamin Lee, M.D., Ph.D.
2:00-3:30 p.m.	616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies—Menin Inhibitors in AML	Ballroom 20CD (San Diego Convention Center)
3:15-4:00 p.m.	Abstract 216: Phase I/II Study of the All-Oral Combination of Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax (SAVE) in R/R AML	Ghayas Issa, M.D.
2:00-3:30 p.m.	617. Acute Myeloid Leukemias: Commercially Available Therapies—Impact of Molecularly-Targeted Agents in AML	Seaport Ballroom EFGH (Manchester Grand Hyatt San Diego)
2:30-2:45 p.m.	Abstract 219: A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Hematologic Malignancies: A 2024 Update	Jennifer Marvin-Peek, M.D.
2:45-3:00 p.m.	Abstract 220: Long-Term Survival Outcomes and Cytogenetic/Molecular Patterns of Relapse in Adults with FLT3-Mutated AML Receiving Frontline Triplet Therapy with a Hypomethylating Agent, Venetoclax and FLT3 Inhibitor	Nicholas Short, M.D.
2:00-3:30 p.m.	634. Myeloproliferative Syndromes: Clinical and Epidemiological—Personalized and Molecular Approaches in Myeloproliferative Neoplasms— Risk Stratification and Therapeutic Implications	Ballroom 20AB (San Diego Convention Center)
	Moderator	Lucia Masarova, M.D.
2:00-3:30 p.m.	Distinguished Abstract Achievement Award Ceremony	Halls G-H - Blood Journals Studio (San Diego Convention Center)
	Moderator	Christopher Flowers, M.D.
3:30-4:00 p.m.	Hemato-Logic: How to Share Your Cases with the ASH Image Bank and Blood Work	Halls G-H - Blood Journals Studio (San Diego Convention Center)
	Moderator	Sanam Loghavi, M.D.
4:00-5:30 p.m.	618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: Functional Genomics in Prognosis and Novel Therapies	Seaport Ballroom ABCD (Manchester Grand Hyatt San Diego)
5:15-5:30 p.m.	Abstract 330: TP53 Mutations within T Cells Induce T-Cell Exhaustion and Functional Impairment in TP53 Mutant AML	Li Li, M.D., Ph.D.
4:00-5:30 p.m.	636. Myelodysplastic Syndromes: Basic and Translational—Disease Mechanisms and Therapeutic Vulnerabilities in Molecular Genetic Subtypes of MDS	Ballroom 20CD (San Diego Convention Center)
4:45-5:00 p.m.	Abstract 346: Clonal Origin of Therapy-Related Myeloid Neoplasms After Autologous Stem Cell Transplant	Hidetaka Uryu, M.D., Ph.D.
4:00-5:30 p.m.	637. Myelodysplastic Syndromes: Clinical and Epidemiological—Defining and Treating Low Risk MDS	Ballroom 20AB (San Diego Convention Center)
4:15-4:30 p.m.	Abstract 350: Long-Term Response Analysis of Transfusion Independence in Erythropoiesis Stimulating Agent-Naive Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes Treated with Luspatercept Vs Epoetin Alfa in the COMMANDS Trial	Guillermo Garcia-Manero, M.D.
5:00-5:15 p.m.	Abstract 353: Preliminary Safety and Biomarker Results of the NLRP3 Inflammasome Inhibitor DFV890 in Adult Patients with Myeloid Diseases: A Phase 1b Study	

5:30-7:30 p.m.	Poster I Presentations. See the list of posters starting on page ##.	Halls G-H (San Diego Convention Center)
Sunday, December 8		
8:00-9:00 a.m.	How I Treat: Acute Myeloid Leukemia with Targetable Mutations (ticketed session)	Aqua 314 (Hilton San Diego Bayfront)
	How I Treat: Acute Myeloid Leukemia with Targetable Mutations	Courtney DiNardo, M.D.
9:30-11:00 a.m.	615. Acute Myeloid Leukemias: Clinical and Epidemiological—Frailty, Age, and Care Provisions-Impact on AML Outcomes	Seaport Ballroom ABCD (Manchester Grand Hyatt San Diego)
9:45-10:00 a.m.	Abstract 446: Safety and Efficacy of G-CSF with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia: A Subgroup Analysis of the Phase II Trial of Venetoclax in Combination with Cladribine, Idarubicin, and Cytarabine	Ian Bouligny, M.D.
9:30-11:00 a.m.	621. Lymphomas: Translational Molecular and Genetic—Single-Cell and Spatial Analyses in Aggressive and T Cell Lymphomas	Marriott Grand Ballroom 5-6 (Marriott Marquis San Diego Marina)
10:30-10:45 a.m.	455: An Integrated Spatial, Codex, and Genomic Analysis Predicts Responsiveness and Survival in the Phase II Combination of Pembrolizumab and Romidepsin in PTCL	Ranjit Nair, M.D.
9:30-11:00 a.m.	626. Aggressive Lymphomas: Clinical and Epidemiological—CARs, Bispecifics, and ADCs—Progress and Challenges in Aggressive B Cell Lymphoma	Marriott Grand Ballroom 8-9 (Marriott Marquis San Diego Marina)
10:15-10:30 a.m.	472: Real-World (RW) Outcomes of Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) and Secondary Central Nervous System (sCNS) Involvement from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry	Sairah Ahmed, MD
9:30-11:00 a.m.	721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Optimizing Conditioning and Donor Selection in Allogeneic Stem Cell Transplantation	Room 6B (San Diego Convention Center)
9:45-10:00 a.m.	506: Myeloablative Fractionated Busulfan, Fludarabine, Cladribine, Thiotepea and Venetoclax (Cladillac) Conditioning Regimen for Very High-Risk AML/MDS: A Phase II Trial	Uday Papat, M.D.
9:30-11:00 a.m.	908. Outcomes Research: Myeloid Malignancies—Social and Economic Disparities in Treatments, Outcomes and Financial Toxicity	Grand Hall B (Manchester Grand Hyatt San Diego)
	Moderator	Warren Fingrut, M.D.
Noon-1:30 p.m.	627. Aggressive Lymphomas: Pharmacologic Therapies—New R-CHOP Combinations for Treatment-Naive DLBCL	Ballroom 20AB (San Diego Convention Center)
12:30-12:45 p.m.	Abstract 579: Golcadomide (GOLCA) Plus R-CHOP Has High Minimal Residual Disease (MRD) Negativity Across High-Risk, Untreated Aggressive B-Cell Lymphoma (a-BCL)	Jason Westin, M.D.
Noon-1:30 p.m.	906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders—Driving the CARs Home—Real-World Safety and Outcomes of CAR-T Cell Therapies	Marriott Grand Ballroom 2-4 (Marriott Marquis San Diego Marina)
1:00-1:15 p.m.	611: Risk Analysis of Cytokine Release Syndrome, Immune Effector Cell-Associated Neurotoxicity Syndrome, and Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-like Syndrome in BiTE Therapy Vs CAR-T Therapy Using Real World Data	Alexandra Elias
1:30-2:00 p.m.	Global Hematology Collaboration: Advancing Diversity and Leadership in Clinical Research	Sails Pavilion - ASH Health Equity Studio (San Diego Convention Center)

	Luis Enrique Malpica Castillo, M.D.	
4:30-5:45 p.m.	Biology Underlying Disparities in Lymphoid Malignancies	Pacific Ballroom Salons 18-19 (Marriott Marquis San Diego Marina)
	Co-Chair	Christopher Flowers, M.D.
	Tumor Sequencing to Investigate Disparities in Non-Hodgkin Lymphoma	
4:30-6:00 p.m.	622. Lymphomas: Translational—Non-Genetic: Demystifying the Complexity of the Lymphoma Tumor Microenvironment and Immune Responses	Pacific Ballroom Salons 15-17 (Marriott Marquis San Diego Marina)
4:30-4:45 p.m.	643: Comprehensive Characterization and Validation of the Tumor Microenvironment in Patients with Relapsed/Refractory Large B-Cell Lymphoma Identifies Subgroups with Greatest Benefit from CD19 CAR T-Cell Therapy	Xubin Li, Ph.D.
4:30-6:00 p.m.	637. Myelodysplastic Syndromes: Clinical and Epidemiological—Treatment and Prognostication of MDS	Harbor Ballroom DEFG (Manchester Grand Hyatt San Diego)
4:30-4:45 p.m.	661: Oral Decitabine/Cedazuridine in Patients with MDS and <i>TP53</i> Mutations: A Propensity Score Matching Analysis from the Phase II and III Trials	Samuel Urrutia, M.D.
4:45-5:00 p.m.	662: Results from a Phase I Open-Label Dose Escalation and Expansion Trial of Oral Azacitidine + Cedazuridine (ASTX030) in Patients with Myelodysplastic Syndromes (MDS) and MDS/Myeloproliferative Neoplasms (MPN)	Guillermo Garcia-Manero, M.D.
6:00-8:00 p.m.	Poster Session II Presentations. See the list of posters starting on page ##.	Halls G-H (San Diego Convention Center)
Monday, Dec. 9		
10:30 a.m.-noon	604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms—Resistance to Standard and Novel Therapies	Seaport Ballroom ABCD (Manchester Grand Hyatt San Diego)
11:45 a.m.-noon	Abstract 726: Mitigating Therapy-Related Myeloid Neoplasia in p53-Mutant Clones Through Targeted DNA Repair Pathway Inhibition with PARP Inhibitors	Rasoul Pourebrahim, M.D., Ph.D.
10:30 a.m.-noon	612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Look into the Crystal B-ALL: Genetic, Phenotypic and Dynamic Outcome Predictors in Lymphoblastic Leukemia	Seaport Ballroom ABCD (Manchester Grand Hyatt San Diego)
10:30-10:45 a.m.	Abstract 727: Early Achievement of Deep Measurable Residual Disease (MRD) Negativity Identifies Patients with B-Cell Acute Lymphoblastic Leukemia (ALL) Who Have Excellent Long-Term Outcomes and Do Not Benefit from Allogeneic Stem Cell Transplant, Irrespective of Baseline High-Risk Cytomolecular Features	Walid Macaron, M.D.
10:45-11:00 a.m.	Abstract 728: Older Age and TP53 Mutations Are Predictors for the Development of Therapy-Related Myeloid Neoplasms in Adults Undergoing Frontline Therapy for Acute Lymphoblastic Leukemia	Roberta Santos Azevedo, M.D.
10:30 a.m.-noon	616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: New Treatment Approaches for AML	Grand Hall B (Manchester Grand Hyatt San Diego)
	Moderator	Naval Daver, M.D.
10:45-11:00 a.m.	Abstract 734: A Phase II Trial of Venetoclax in Combination with Cladribine, Idarubicin, and Cytarabine in Newly Diagnosed Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome	Ian Bouligny, M.D.
11:15-11:30 a.m.	Abstract 735: Phase Ib/II Study of Magrolimab (Magro), Azacitidine (AZA) and Venetoclax (VEN) in Patients (pts) with Newly Diagnosed (ND)	Sankalp Arora, M.B.B.S.

	Older/Unfit or High Risk Acute Myeloid Leukemia (AML) and Relapsed Refractory (R/R) AML: Final Clinical Data and Genomic Markers of Resistance/Relapse	
10:30 a.m.-noon	651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational—Uncovering New Targets and Disease Mechanisms in Myeloma	Pacific Ballroom Salons 24-26 (Marriott Marquis San Diego Marina)
11:30-11:45 a.m.	Abstract 767: Single-Cell Multi-Omic Profiling of Patients with BCMA-Targeted Therapy Identifies Molecular and Cellular Factors Associated with Responsiveness and Treatment Effects	Minghao Dang, Ph.D.
10:30 a.m.-noon	654. Multiple Myeloma: Pharmacologic Therapies—Refining the Evidence: Randomized Trials in Multiple Myeloma	Pacific Ballroom Salons 21-22 (Marriott Marquis San Diego Marina)
10:45-11:00 a.m.	Abstract 770: Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Analyses of Minimal Residual Disease (MRD) Negativity Dynamics in the Phase 3 Imroz Study	Robert Orlowski, M.D., Ph.D.
2:45-4:00 p.m.	Adult ALL Advancements: Optimizing Cure in 2024	Ballroom 20AB (San Diego Convention Center)
	Transplant in ALL: Who, When, and How?	Partow Kebriaei, M.D.
2:45-4:15 p.m.	201. Granulocytes, Monocytes, and Macrophages: From Inflammation to Hemophagocytic Lymphohistiocytosis	Room 6DE (San Diego Convention Center)
2:45-3:00 p.m.	Abstract 805: ELA026, a Monoclonal Antibody Targeting Signal Regulatory Protein- $\alpha/\beta1/\gamma$, Rapidly Controls Inflammation and Improves 2-Month Survival in Treatment-Naive Malignancy-Associated Hemophagocytic Lymphohistiocytosis	Abhishek Maiti, M.B.B.S.
2:45-4:15 p.m.	613. Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Treatment of BCR—ABL+ and T Cell Diseases	Marriott Grand Ballroom 2-4 (Marriott Marquis San Diego Marina)
3:15-3:30 p.m.	Abstract 837: Blinatumomab and Ponatinib for Adults with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Updated Results and Predictors of Relapse	Nicholas Short, M.D.
2:45-4:15 p.m.	615. Acute Myeloid Leukemias: Clinical and Epidemiological: Genetic Markers and Outcomes in AML	Grand Hall C (Manchester Grand Hyatt San Diego)
2:45-3:00 p.m.	Abstract 841: Characteristics and Outcomes of Patients (pts) with Acute Myeloid Leukemia (AML) and FLT3-Tyrosine Kinase Domain (TKD) Mutations	Sankalp Arora, M.B.B.S.
2:45-4:15 p.m.	623. Mantle Cell, Follicular, Waldenström's, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological—Clinical Trials for Marginal Zone Lymphoma, Waldenström's Macroglobulinemia and Hairy Cell Leukemia	Marriott Grand Ballroom 11-13 (Marriott Marquis San Diego Marina)
4:00-4:15 p.m.	Abstract 864: 5-Year Follow-up Analysis from ZUMA-5: A Phase II Trial of Axicabtagene Ciloleucef (Axi-Cel) in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma	Sattva Neelapu, M.D.
2:45-4:15 p.m.	636. Myelodysplastic Syndromes: Basic and Translational—Novel Mechanisms of Aberrant Hematopoiesis and Immune Evasion in MDS	Grand Hall D (Manchester Grand Hyatt San Diego)
4:00-4:15 p.m.	Abstract 882: Novel p53 Mutant Mouse Model Recapitulates the Biology of Human Therapy-Related Myeloid Neoplasms	Rasoul Pourebrahim, M.D., Ph.D.
2:45-4:15 p.m.	642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Treating Refractory Disease—Novel Agents and Quality-of-Life	Marriott Grand Ballroom 5-6 (Marriott Marquis San Diego Marina)
3:45-4:00 p.m.	Abstract 887: Lisocabtagene Maraleucef (liso-cel) Combined with Ibrutinib (ibr) for Patients (pts) with Relapsed or Refractory (R/R) Chronic	William Wierda, M.D., Ph.D.

	Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Primary Results from the Open-Label, Phase I/II Transcend CLL 004 Study	
2:45-4:15 p.m.	703. Cellular Immunotherapies other than CAR-T Cells: Basic and Translational—Enhancing NK Cell Therapeutics	Marriott Grand Ballroom 8-9 (Marriott Marquis San Diego Marina)
	Moderator	May Daher, M.D.
2:45-4:15 p.m.	907. Outcomes Research: Plasma Cell Disorders: Bispecific Antibodies and CAR-T Therapies in Myeloma-The Yin and Yang of Powerful Therapies	San Diego Ballroom AB (Marriott Marquis San Diego Marina)
3:30-3:45 p.m.	Abstract 934: Outcomes of Elderly Patients with Relapsed Refractory Multiple Myeloma (RRMM) Treated with Teclistamab: A Multicenter Study from the U.S. Multiple Myeloma Immunotherapy Consortium	Oren Pasvolsky, M.D.
4:30-5:45 p.m.	Adult CAR-T Outcomes: Beyond the Acronyms (OS, PFS, CRS, ICANS)	Room 24 (San Diego Convention Center)
	Patient-Reported Outcomes After CAR T-Cell Therapy in Patients with Hematological Malignancies	Xin Shelley Wang, M.D.
4:30-6:00 p.m.	613. Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Risk Stratification and CAR-T Therapies	Marriott Grand Ballroom 5-6 (Marriott Marquis San Diego Marina)
5:00-5:15 p.m.	Abstract 963: Obecabtagene autoleucl (obe-cel) for Adult Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL): Deep Molecular Remission May Predict Better Outcomes	Elias Jabbour, M.D.
4:30-6:00 p.m.	617. Acute Myeloid Leukemias: Commercially Available Therapies—Optimizing Regimens in Children/Young Adults and Around the World	Grand Hall B (Manchester Grand Hyatt San Diego)
	Moderator	Farhad Ravandi, M.B.B.S.
4:30-6:00 p.m.	634. Myeloproliferative Syndromes: Clinical and Epidemiological: Advancing MPN Care—Innovative Therapies and Clinical Breakthroughs in Myelofibrosis	Harbor Ballroom DEFG (Manchester Grand Hyatt San Diego)
5:00-5:15 p.m.	Abstract 999: A Phase Ib, Open-Label Study of Add on Therapy with CK0804 in Participants with Myelofibrosis and Suboptimal Response to Ruxolitinib	Lucia Masarova, M.D.
4:30-6:00 p.m.	637. Myelodysplastic Syndromes: Clinical and Epidemiological: Defining and Treating Chronic Myelomonocytic Leukemia	Grand Hall D (Manchester Grand Hyatt San Diego)
5:30-5:45 p.m.	Abstract 1007: Updated Results from a Phase II Study of Vibecotamab, a CD3-CD123 Bispecific T-Cell Engaging Antibody, for MDS or CMML after Hypomethylating Failure and in MRD-Positive AML	Daniel Nguyen, M.D., Ph.D.
4:30-6:00 p.m.	642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological—Frontline Targeted Therapy Combinations	Marriott Grand Ballroom 8-9 (Marriott Marquis San Diego Marina)
5:00-5:15 p.m.	Abstract 1011: Combined Pirtobrutinib, Venetoclax, and Obinutuzumab as First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)	Nitin Jain, M.D.
5:45-6:00 p.m.	Abstract 1014: Atezolizumab Combined with Venetoclax and Obinutuzumab for Frontline CLL	Patrick Reville, M.D.
4:30-6:00 p.m.	723. Allogeneic Transplantation: Long-Term Follow up and Disease Recurrence: Novel Therapies to Prevent and Treat Disease Relapse	Room 6A (San Diego Convention Center)
5:00-5:15 p.m.	Abstract 1047: A Phase I Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with High Risk or Refractory/Relapsed Acute Myeloid Leukemia Following Allogeneic Stem Cell Transplantation	Gheath Alatrash, Ph.D., D.O.
4:30-6:00 p.m.	803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: Pioneering Tools for Tomorrow's Breakthroughs	Marriott Grand Ballroom 2-4 (Marriott Marquis San Diego Marina)

5:00-5:15 p.m.	Abstract 1059: Multimodal Spatial Transcriptomic Profiling Elucidates Niche-Specific Dynamics in Medullary and Extramedullary Acute Myeloid Leukemia	Enes Dasdemir
6:00-8:00 p.m.	Poster III Presentations. See the list of posters starting on page ##.	Halls G-H (San Diego Convention Center)

Posters		
201. Granulocytes, Monocytes, and Macrophages: Poster III		
Abstract 3913: Patients (pts) with Optimized Hemophagocytic Lymphohistiocytosis (HLH) Inflammatory (OHI) Index-Confirmed Diagnosis of Malignancy-Associated HLH (mHLH) and Emapalumab Treatment		Naval Daver, M.D.
301. Platelets and Megakaryocytes: Basic and Translational: Poster III		
Abstract 3926: Large Scale Manufacturing of GMP Grade Cord Blood Derived Megakaryocytes for Chemotherapy Induced Thrombocytopenia		Hila Shaim, M.D.
506. Bone Marrow Microenvironment: Poster I		
Abstract 1301: Spatial Analysis of Human p53 Mutated AML Bone Marrow Reveals Novel MRD Clusters and Spatial Microenvironmental Features of p53 Mutated AML		Hideaki Mizuno, M.D., Ph.D.
602. Myeloid Oncogenesis: Basic: Poster I		
1349 ASXL1 Mutations in AML Are Associated with a Distinct Epigenetic State Which Highlights Vulnerabilities to Specific Epigenetic-Targeted Agents		Christopher Peter Mill, Ph.D.
604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster I		
Abstract 1373: Identifying "Druggable" Targets and Preclinically Overcoming Non-Genetic/Adaptive Resistance to Menin Inhibitors in AML with MLL1r or mtNPM1		Warren Fiskus, Ph.D.
Abstract 1400: Targeting Lipid Droplet Biogenesis to Enhance Ferroptosis in Acute Myeloid Leukemia		Liang Zhang, Ph.D.
604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster II		
Abstract 2749: Efficacy of a Novel BCL-XL Degrader, DT2216, in Preclinical Models of Post-Myeloproliferative Neoplasm Secondary AML		Zhe Wang, M.D., Ph.D.
Abstract 2753: Elucidating Transcriptional Heterogeneity in Venetoclax Resistant AMLs		Natalia Baran, M.D., Ph.D.
Abstract 2755: Targeting Co-Regulatory Feedback Loop of MYC and GSPT1 By MYC/GSPT1 Dual Degradation Is Synthetic Lethal in Combination with Ven/Aza in TP53 Mutant Acute Myeloid Leukemia Stem and Progenitor Cells		Yuki Nishida, M.D., Ph.D.
Abstract 2759: ERK1/2 Inhibition Mediates Bax Dependent Proteolysis of OPA1 and Induces Mitochondrial Cristae Remodeling to Overcome Resistance to Venetoclax		Priyanka Sharma, Ph.D.
Abstract 2765: Molecular Interactions between Mitochondrial Ferroptosis and Apoptosis Pathways in Acute Myeloid Leukemia		Kazuharu Kamachi, M.D., Ph.D.
Abstract 2766: Transcriptomic Signature of Resistance to Decitabine/Venetoclax in AML Patients		Yoko Tabe, M.D., Ph.D.
Abstract 2777: Safety and Efficacy of a Novel Mammalian-Derived Asparaginase without Glutaminase Activity in Combination with Venetoclax for Acute Myeloid Leukemia		Dhabya Majid
604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster III		
Abstract 4155: Reactivation of p53 in TP53-Y220C Mutant AML: Mechanism of Action and Mechanism-Based Drug Combinations		Bing Carter, Ph.D.
05. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster II		
Abstract 2786: Protein Degrader WH25244 Eliminates Venetoclax Resistance Factors: Mutant or Hyperphosphorylated BCL2, and BCL-XL		Daisy Diaz Rohena
612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Poster I		
Abstract 1427: Evaluating the Safety of Tyrosine Kinase Inhibitor Discontinuation in Adult Patients with Ph+ ALL Not Undergoing Allogeneic Transplant		Eitan Kugler, M.D., Ph.D.
612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Poster III Clinically Relevant Abstract		
Abstract 4182: CNS Involvement in Adult Patients with B-Cell Acute Lymphoblastic Leukemia		Susan Wu, M.D.
613. Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Poster II		

Abstract 2810: Allogeneic Hematopoietic Stem Cell Transplantation Following CAR T Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia	Natalie Rafaeli, M.D.
Abstract 2811: Updated Results of the Combination of Mini-Hyper-CVD with Inotuzumab Ozogamicin and Blinatumomab in Patients with Relapsed/Refractory B-Cell ALL	Fadi Haddad, M.D.
Abstract 2821: Ponatinib Monotherapy after Combination with Chemotherapy in Patients with Newly Diagnosed Ph+ ALL: Post Hoc Subgroup Analysis of the Phase 3 Phallcon Study	Elias Jabbour, M.D.
613. Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Poster I	
Abstract 1439: Updated Results from a Phase II Study Hyper-CVAD, with or without Inotuzumab Ozogamicin, and Sequential Blinatumomab in Patients with Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia	Daniel Nguyen, M.D., Ph.D.
Abstract 1440: Single-Agent Subcutaneous Blinatumomab for Advanced B-Cell Acute Lymphoblastic Leukemia: Long-Term Follow-up from a Phase Ib Dose Expansion Cohort	Elias Jabbour, M.D.
Abstract 1441: Low Intensity Mini-Hypercvd (mHCVD), Inotuzumab Ozogamicin (Ino) with/without Blinatumomab (Blina) in Older Patients with Newly Diagnosed Philadelphia Negative B-Cell Acute Lymphoblastic Leukemia (B-ALL): 10 Years Update	Jayastu Senapati, M.D., D.M., M.B.B.S.
Abstract 1442: Chemotherapy Free Regimen of Inotuzumab Ozogamicin and Blinatumomab in Frontline Therapy of Older Patients with Philadelphia Negative B-Cell Acute Lymphoblastic Leukemia	
613. Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Poster III	
Abstract 4194: Phase II Study of Inotuzumab Ozogamicin for the Treatment of Measurable Residual Disease-Positive B-Cell Acute Lymphoblastic Leukemia: 3-Year Update	Fadi Haddad, M.D.
Abstract 4198: A Phase I/II Study of Mini-Hyper-CVD, Venetoclax and Navitoclax in Patients with Relapsed/Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia	Nicholas Short, M.D.
Abstract 4207: Combination Therapy with Nelarabine, Peg-Asparaginase and Venetoclax for Adults Patients with Relapsed/Refractory T-Cell ALL	Niranjan Shiwaji Khaire, M.B.B.S.
614. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers, and Minimal Residual Disease in Diagnosis and Prognosis: Poster I	
Abstract 1461: Outcomes of Adult Patients with Philadelphia Negative B-Cell Acute Lymphoblastic Leukemia (B-ALL) Having Myeloid Type Mutations Treated with Inotuzumab/Blinatumomab Containing Frontline Regimens	Jayastu Senapati, M.D., D.M., M.B.B.S.
Abstract 1465: Clearance of Very Low Levels of Measurable Residual Disease with Blinatumomab Significantly Improves Outcomes in B-Cell Acute Lymphoblastic Leukemia	Daniel Nguyen, M.D., Ph.D.
614. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers, and Minimal Residual Disease in Diagnosis and Prognosis: Poster III	
Abstract 4219: Single Cell Profiling of Ph-Positive Acute Lymphoblastic Leukemias Reveals Distinct Cells of Origin	Sogand Sajedi, Ph.D
Abstract 4224: Genomic Profiling of T-Cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL) for Identification of Driver Aberrations Using Combined Next Generation Sequencing and Optical Genome Mapping in Clinical Diagnostic Laboratory	Iman Sarami, M.D.
615. Acute Myeloid Leukemias: Clinical and Epidemiological: Poster I	
Abstract 1472: Less May be More: The Impact of Post-Remission Intensive (IC) Consolidation Cycles on Outcomes in Newly Diagnosed Acute Myeloid Leukemia Receiving IC + Venetoclax	Jennifer Marvin-Peek, M.D.
615. Acute Myeloid Leukemias: Clinical and Epidemiological: Poster II	
Abstract 2851: Treatment Intensity in Acute Myeloid Leukemia with Extramedullary Disease	Jennifer Marvin-Peek, M.D.
Abstract 2853: Clinical Outcomes Associated with NPM1 Mutations in Newly Diagnosed AML	Aziz Farhat, M.D.
AbstractL 2857: Incidence, Characteristics, and Outcomes of Patients with Newly Diagnosed, De Novo KIT-Mutated Non-Core Binding Factor Acute Myeloid Leukemia without Systemic Mastocytosis	Eitan Kugler, M.D., Ph.D.
Abstract 2861: Establishing Benchmarks for Relapse-Free and Overall Survival Among Patients (Pts) with Newly Diagnosed AML Not Undergoing Allogeneic Stem Cell Transplantation (SCT) in First Remission	
615. Acute Myeloid Leukemias: Clinical and Epidemiological: Poster III	
Abstract 4251: Outcomes of Patients with Treated Secondary AML: A High Risk Subtype of AML Arising from Previously Treated Myeloid Neoplasms That Warrants an Independent Prognostic Designation	Jayastu Senapati, M.D., M.B.B.S.

616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: Poster I	
Abstract 1497: Long-Term Follow-up of Crenolanib Maintenance after Allogeneic Transplantation in Newly Diagnosed and Relapsed FLT3 Mutated AML	Betul Oran, M.D.
616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: Poster II	
Abstract 2878: A Phase I Study of the Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)	Yesid Alvarado Valero, M.D.
Abstract 2883: Clinical Outcomes Using Frontline Triplet Regimens for Newly Diagnosed IDH-Mutated Acute Myeloid Leukemia (AML): A Pooled Analysis of Two Phase Ib/2 Clinical Trials	Jennifer Marvin-Peek, M.D.
616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: Poster III	
Abstract 4255: Phase I Safety and Efficacy of Tuspentinib Plus Venetoclax Combination Therapy in Study Participants with Relapsed or Refractory Acute Myeloid Leukemia (AML) Support Exploration of Triplet Combination Therapy of Tuspentinib Plus Venetoclax and Azacitidine for Newly Diagnosed AML	Naval Daver, M.D.
Abstract 4162: Final Results of a Phase II Study of Uproleselan Combined with Cladribine and Low-Dose Cytarabine for Patients with Treated Secondary Acute Myeloid Leukemia (ts-AML)	Caitlin Rausch, Pharm.D.
Abstract 4263: Phase I/II Study of Quizartinib, Venetoclax, and Decitabine Triple Combination in FLT3-ITD Mutated AML	Musa Yilmaz, M.D.
617. Acute Myeloid Leukemias: Commercially Available Therapies: Poster I	
Abstract 1511: Phase Ib/II Study of CPX-351 in Combination with Venetoclax in Patients with Newly Diagnosed, High Risk Acute Myeloid Leukemia	Tapan Kadia, M.D.
Abstract 1513: Gemtuzumab Ozogamicin Added to Fludarabine, Cytarabine and G-CSF (FLAG-GO) Leads to Superior Molecular Response and Survival Outcomes Than Idarubicin (FLAG-IDA): 200 Patients Long-Term Follow up	Jayastu Senapati, M.D., D.M., M.B.B.S.
617. Acute Myeloid Leukemias: Commercially Available Therapies: Poster II	
Abstract 2896: Fully Oral Combination of Decitabine/Cedazuridine (ASTX727) Plus Venetoclax for the Treatment of Newly Diagnosed Acute Myeloid Leukemia in Patients Ineligible for Intensive Chemotherapy	Alexandre Bazinet, M.D.
Abstract 2901: A Phase II Study of Cladribine, Idarubicin, and Cytarabine (CLIA) in Combination with Gilteritinib for Patients with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia	Hannah Goulart, M.D.
Abstract 2903: Combination of CPX-351 and Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Acute Myeloid Leukemia and Post Hypomethylating Agent (HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS)	Jayastu Senapati, M.D., D.M., M.B.B.S.
Abstract 2906: FLAG IDA Venetoclax in Newly Diagnosed Pediatric and AYA Patients with AML	Reeja Raj, D.O.
617. Acute Myeloid Leukemias: Commercially Available Therapies: Poster III	
Abstract 4271: Interim Results of the Phase II Study Investigating CPX-351 in Combination with Ivosidenib for Patients with IDH1-Mutated Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome	Jennifer Croden, M.D.
Abstract 4272: Phase Ib/II Study of CPX-351 Plus Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)	Vanthana Bharathi, M.D.
Abstract 4277: Personalized Oral Maintenance Therapy with Decitabine/Cedazuridine (ASTX727) Combined with a Molecularly Targeted Agent (Venetoclax, Gilteritinib, Ivosidenib, or Enasidenib) in Acute Myeloid Leukemia in First Remission	Alexandre Bazinet, M.D.
Abstract 4293: Patterns of Relapse Following Venetoclax-Based Therapies of Differing Intensity in Acute Myeloid Leukemia	Naszrin Arani, M.D.
618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: Poster II	
Abstract 2912: Blood-Based Proteomic Profiling Identifies Osmr As a Novel Biomarker	Hussein Abbas, M.D., Ph.D.
621. Lymphomas: Translational Molecular and Genetic: Poster I	
Abstract 1572: Impact of Flow Cytometry-Based Measurable Residual Disease Clearance Kinetics in Patients with Acute Myeloid Leukemia Undergoing Intensive Chemotherapy	Wei-Ying Jen, M.D.
619. Acute Myeloid Leukemias: Disease Burden and Minimal Residual Disease in Prognosis and Treatment: Poster III	

Abstract 4336: Myeloid Progenitor Cells with Preleukemic Immunophenotypes Are Common in Myelodysplasia-Related and NPM1-mutated Acute Myeloid Leukemia and Should Not be Interpreted As Measurable Residual Disease	Sanam Loghavi, M.D.
621. Lymphomas: Translational – Molecular and Genetic: Poster I	
Abstract 1584: Characterization of Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma Using Single Cell Transcriptomic Analysis	Minghao Dang, Ph.D.
Abstract 1598: A Cell Surface Heat Shock Protein 70 (csHSP70) – CD3 Bispecific T-Cell Engaging Antibody Exhibits Anti-Tumor Efficacy in Pre-Clinical T-Cell Lymphoma and Multiple Myeloma Models	Upasana Ray, Ph.D.
621. Lymphomas: Translational Molecular and Genetic: Poster II	
Abstract 2970: Collective Analysis of Genomic Data Sets to Assess the Impact of Eligibility Criteria on Molecular Subsets in First-Line Clinical Trials for Patients with Diffuse Large B-Cell Lymphoma	Robert Andrew Harkins, M.D.
Abstract 2982: Use of Molecular Immune Signatures for Frontline Treatment Selection in Patients with Advanced Stage Follicular Lymphoma	Tony Zhuang, M.D.
621. Lymphomas: Translational Molecular and Genetic: Poster III	
Abstract 4364: Evaluating the Clinical Utility of Real-Time Comprehensive Whole Exome Sequencing and RNA-Seq for Patients with Diffuse Large B-Cell Lymphoma	Dai Chihara, M.D., Ph.D.
622. Lymphomas: Translational - Non-Genetic: Poster II	
Abstract 2994: Evaluating Full Antitumor Activities of Monoclonal Antibody and Innate Immune Cells in Relapsed/Refractory Mantle Cell Lymphoma Using Ex Vivo Organoid Platform	Lei Nie, M.D.
Abstract 3000: Peripheral Blood CAR T-Cell Level Using a Clia-Validated Assay Is Prognostic for Treatment Response and Icars in Large B-Cell Lymphoma	Anath Lionel, M.D., Ph.D.
622. Lymphomas: Translational Non-Genetic: Poster III	
Abstract 4373: Generation of a Patient Derived T-Cell Prolymphocytic Leukemia Xenograft Model to Evaluate Pre-Clinical Treatment with Small Molecule Inhibitors In Vivo	Claudia Kettlun, Ph.D.
Abstract 4377: Radiation Therapy and Monocyte Activation in Large B-Cell Lymphoma Patients Treated with CAR T-Cell Therapy	Penny Fang, M.D.
623. Mantle Cell, Follicular, Waldenström's, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster II	
Abstract 3024: Prognostic Significance of TP53 Mutations in Lymphoplasmacytic Lymphoma	Anath Lionel, M.D., Ph.D.
Abstract 3038: Acalabrutinib with Rituximab Is Highly Effective First Line Treatment for Older Patients with Mantle Cell Lymphoma	Preetesh Jain, M.D., M.B.B.S., Ph.D., D.M.
623. Mantle Cell, Follicular, Waldenström's, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster III	
Abstract 4388: Five-Year Outcomes of Patients (Pts) with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Treated with Brexucabtagene Autoleucel (Brexu-cel) in ZUMA-2 Cohorts 1 and 2	Michael Wang, M.D.
Abstract 4396: Treatment Patterns and Real World Outcomes with Clinical Trials for Patients with Follicular Lymphoma across Lines of Therapy	Neha Akkad, M.D.
625. T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological: Poster I	
Abstract 1679: Large Cell Transformation in Mycosis Fungoides & Sezary Syndrome: An Analysis of 445 Cases	Rishabh Lohray, M.D.
Abstract 1680: Survival Outcomes and Genetic Assessment in Patients with Dual Diagnoses of B-Cell and T-Cell Lymphomas	Anath Lionel, M.D., Ph.D.
625. T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological: Poster III	
Abstract 4499: A Phase II Clinical Study Exploring the Safety and Efficacy of the Oral PI3K \hat{I} Inhibitor, Linnerlisib, in Relapsed Refractory T Cell Lymphoma	Swaminathan Iyer, M.D.
626. Aggressive Lymphomas: Clinical and Epidemiological: Poster III	
Abstract 4454: Retreatment with R-CHOP-like Therapy Is Active with Durable Responses in Patients with Late Relapse of Diffuse Large B-Cell Lymphoma	Eduardo Edelman Saul, M.D.
Abstract 4462: Utilizing Synthetic Individual Patient Level Cohorts from Machine Learning on Clinical Trials to Define Endpoints for Bispecific Trials in Large B-Cell Lymphoma	Dai Chihara, M.D., Ph.D.
628. Aggressive Lymphomas: Cellular Therapies: Poster I	

Abstract 1743: A Phase 1/2 Study of a ROR1-Targeting CAR T Cell Therapy (ONCT-808) in Adult Patients with Relapsed/Refractory (R/R) Aggressive B Cell Lymphomas (BCL)	Michael Wang, M.D.
628. Aggressive Lymphomas: Cellular Therapies: Poster III	
Abstract 4506: Impact of Pre-Treatment Liver-Related Factors on Clinical Outcomes after CAR T-Cell Therapy for Lymphoma	Anath Lionel, M.D., Ph.D.
Abstract 4508: Impact of Pre-Existing Mental Health Disorders (MHD) on CAR T-Cell Therapy Outcomes in Patients with Large B-Cell Lymphoma	Sushanth Gouni, M.D.
631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Poster I	
Abstract 1760: Temporal Dynamics of Bone Marrow Fibrocytes in the Progression of Primary Myelofibrosis	Ivo Veletic, M.D.
631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Poster II	
Abstract 3142: Evaluation of the Lethal Activity and Its Mechanism of Tasquinimod in Advanced Myeloproliferative Neoplasm (MPN) in Blastic Phase	Warren Fiskus, Ph.D.
632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster II	
Abstract 3151: Olverembatinib 1(HQP1351) Overcomes Resistance/Intolerance to Asciminib and Ponatinib in Patients (pts) with Heavily Pretreated Chronic-Phase Chronic Myeloid Leukemia (CP&CML): A 1.5-Year Follow-up Update with Comprehensive Exposure-Response (E-R) Analyses	Elias Jabbour, M.D.
Abstract 3156: A Retrospective Analysis of Ponatinib-Based Therapy in Patients with Myeloid Blast Phase Chronic Myeloid Leukemia: Responses Rates, Outcomes and Patterns of Relapse	Omer Karrar
636. Myelodysplastic Syndromes: Basic and Translational: Poster I	
Abstract 1816: Distinct Impact of Platinum Chemotherapies on the Fitness and Genome of Hematopoietic Stem Cells and the Risk of Therapy-Related Myeloid Neoplasms	Jeremy Connors, M.D.
637. Myelodysplastic Syndromes: Clinical and Epidemiological: Poster I	
Abstract 1832: Changes in Red Blood Cell Transfusion Burden with Luspatercept Versus Epoetin Alfa in Patients with Lower-Risk Myelodysplastic Syndromes in the Phase 3, Open-Label, Randomized, Controlled COMMANDS Trial	Guillermo Garcia-Manero, M.D.
Abstract 1837: Comprehensive Characteristics and Outcomes of Myeloid Neoplasms Following Chimeric Antigen Receptor T-Cell Therapy for Other Hematologic Malignancies	Danielle Hammond, M.D.
637. Myelodysplastic Syndromes: Clinical and Epidemiological: Poster III	
Abstract 3204: Landscape and Clinicopathologic Features of RAS Pathway Mutations in Chronic Myelomonocytic Leukemia	Guillermo Montalban-Bravo, M.D.
Abstract 3209: Phase I/II Combination Study of Azacitidine and Venetoclax Post Hypomethylating Agents Failure in High Risk MDS and CMML	Julie Braish, M.D.
Abstract 3212: A Phase II Trial of Azacitidine with Ipilimumab, Nivolumab, or Ipilimumab and Nivolumab with or without Azacitidine in Relapsed or Refractory Myelodysplastic Syndrome	Ian Bouligny, MD
Abstract 3225: Preliminary Safety, Efficacy and Molecular Characterization in Patients with Higher-Risk Myelodysplastic Syndrome Treated with Single Agent Emavusertib (CA-4948)	Guillermo Garcia-Manero, M.D.
637. Myelodysplastic Syndromes: Clinical and Epidemiological: Poster III	
Abstract 4584: Performance of the Molecular International Prognostic Scoring System (IPSS-M) in Myelodysplastic Syndromes Treated with Hypomethylating Agent-Based Therapy: A Multicenter Analysis	Kelly Chien, M.D.
Abstract 4595: R289, a Dual Irak 1/4 Inhibitor, in Patients with Relapsed/Refractory (R/R) Lower-Risk Myelodysplastic Syndrome (LR-MDS): Initial Results from a Phase 1b Study	Guillermo Garcia-Manero, M.D.
Abstract 4601: A Phase II Trial of Azacitidine with Ipilimumab, Nivolumab, or Ipilimumab and Nivolumab in Previously Untreated Myelodysplastic Syndrome	Ian Bouligny, M.D.
641. Chronic Lymphocytic Leukemia: Basic and Translational: Poster I	
Abstract 1850: Impact of Docirbrutinib (AS-1763) Treatment in CLL: Preclinical Data and Early Clinical Biomarkers	Natalia Timofeeva, M.D.
641. Chronic Lymphocytic Leukemia: Basic and Translational: Poster II	
Abstract 3236: Comprehensive Characterization of Inflammatory Cytokines in Chronic Lymphocytic Leukemia Highlight Immune Dysregulation and Associates with MRD	Bofei Wang, Ph.D.

642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster I	
Abstract 1855: Early Obinutuzumab Significantly Increases Bone Marrow Undetectable MRD (10-4 sensitivity) (uMRD4) Rate When Combined with Acalabrutinib and Venetoclax in a Randomized Phase II Trial for Treatment-Naive CLL	William Wierda, M.D., Ph.D.
Abstract 1866: Preliminary Results from a Phase 1b Study of Non-Covalent Pan-Mutant BTK Inhibitor Docirbrutinib (AS-1763) in Patients with Previously Treated B-Cell Malignancies	Nitin Jain, M.D.
Abstract 1868: A Phase II Study of Time-Limited Treatment with Acalabrutinib Plus Obinutuzumab in Patients with Treatment-Naive Chronic Lymphocytic Leukemia	Jan Burger, M.D., Ph.D.
Abstract 1869: Consistently High 5.5-Year Progression-Free Survival (PFS) Rates in Patients with and without Bulky Baseline Lymphadenopathy >5 Cm Are Associated with High Undetectable Minimal Residual Disease (uMRD4) Rates after First-Line Treatment with Fixed-Duration Ibrutinib + Venetoclax for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) in the Phase II CAPTIVATE Study	William Wierda, M.D., Ph.D.
642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster III	
Abstract 4615: Treatment with First-Line Ibrutinib Improves Overall Survival in Patients with Chronic Lymphocytic Leukemia (CLL) and High-Risk Genomic Features to Rates Approximating an Age-Matched US Population: Pooled Analysis of Phase 3 Trials with 10 Years of Follow-up	Jan Burger, M.D., Ph.D.
Abstract 4631: Time-Limited Therapy with Zanubrutinib Plus Rituximab in Patients with Treatment-Naive Chronic Lymphocytic Leukemia: Early Results of an Ongoing Phase II Trial	
651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster II	
Multi-Omic Single-Cell Characterization of Paired and Serial Samples in Responding and Non-Responding Patients Receiving BCMA Bispecific Antibody Therapy for Multiple Myeloma	Minghao Dang, Ph.D.
651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster III	
Abstract 4640: Elucidation of Molecular Mechanisms of Iberdomide and Mezigdomide Resistance in Cell Line Models of Multiple Myeloma	Wei Tan
652. MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster I	
Abstract 1922: Predictive Factors for Transplant Outcomes of Cardiac AL Amyloidosis	Abdullah Faisal Deen
Abstract 1923: Impact of Age on Autologous Stem Cell Transplantation Outcomes for AL Amyloidosis	Sophiya Sami
653. Multiple Myeloma: Clinical and Epidemiological: Poster I	
Abstract 1971: Unveiling Clinical Potential: Exploring Cytogenomic Aberrations through Optical Genomic Mapping in Multiple Myeloma	Christine Ye, MD
653. Multiple Myeloma: Clinical and Epidemiological: Poster II	
Abstract 3337: Predictors and Characterization of Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) in Patients with Multiple Myeloma Receiving Teclistamab	Oren Pasvolsky, M.D.
Abstract 3344: Outcomes of Patients with Multiple Myeloma with Deletion 1p Following Autologous Stem Cell Transplant	
654. Multiple Myeloma: Pharmacologic Therapies: Poster II	
Abstract 3369: Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma: Longer Follow-up and Selected High-Risk Subgroup Analyses of the Linker-MM1 Study	Mansi Shah, M.D.
654. Multiple Myeloma: Pharmacologic Therapies: Poster III	
Abstract 4737: Personalized Neoantigen Peptide Vaccine with or without Lenalidomide for Patients with Intermediate or High Risk Smoldering Multiple Myeloma (SMM) to Prevent Progression to Multiple Myeloma (MM)	Krina Patel, M.D.
Abstract 3344: Outcomes of Patients with Multiple Myeloma with Deletion 1p Following Autologous Stem Cell Transplant	Oren Pasvolsky, M.D.
701. Experimental Transplantation: Basic and Translational: Poster II	
Abstract 3401: Overcoming NK Cell-Mediated Allograft Rejection By Anti-3rd Party Central Memory Veto CD8 T Cells through Down-Regulation of the Activating Receptor DNAM-1 on Alloreactive NK Cells	Wei-Hsin Liu, MD
702. CAR-T Cell Therapies: Basic and Translational: Poster II	

Abstract 3428: Imaging Activated Innate Immune Myeloid Cells in Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) Following CAR T-Cell Therapy	Ajlan Al Zaki, M.D., Ph.D.
703. Cellular Immunotherapies other than CAR-T Cells: Basic and Translational: Poster II	
3435: Developing Novel Cellular Therapies for Cutaneous T Cell Lymphoma (CTCL): Combining Immunopeptidomics and Endogenous T Cell (ETC) Therapy Platforms to Identify and Target Shared CTCL-Associated Antigens	Casey Bermack, M.D., Ph.D.
703. Cellular Immunotherapies other than CAR-T Cells: Basic and Translational: Poster III	
Abstract 4818: Cord-Derived Invariant Natural Killer T Cells As Novel Cell Therapy to Improve the Outcome of Hematopoietic Stem Cell Transplantation	Jin Im, MD, Ph.D.
704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Poster I	
Abstract 2068: NKTR-255 Vs Placebo to Enhance Complete Responses and Durability Following CD19-Directed CAR-T Therapy in Patients with Relapsed/ Refractory (R/R) Large B-Cell Lymphoma (LBCL)	Sairah Ahmed, M.D.
704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Poster III	
Abstract: Phase II Clinical Trial of Off-the-Shelf NK Cells with Allogeneic Stem Cell Transplantation in Patients with High-Risk Myeloid Malignancies	Jeremy Ramdial, M.D.
721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Poster I	
2124: Addition of Inotuzumab Ozogamicin to Melphalan Plus Fludarabine Reduced-Intensity Conditioning Regimen of Allogeneic Transplantation in Patients with Acute Lymphoblastic Leukemia and Aggressive Lymphoid Malignancies: A Phase II Prospective Trial	Issa Khouri, M.D.
721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Poster III	
Abstract 4890: Predictors of Graft-Versus-Host Disease with Post-Transplant Cyclophosphamide	Rima Saliba, Ph.D.
732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster I	
Abstract 2191: Primary Induction Failure Acute Myeloid Leukemia: Immediate Use of Allogeneic Stem Cell Transplantation Vs. Further Induction Chemotherapy	Natalie Rafaeli, M.D.
732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster II	
Abstract 3572: Impact of Post-Remission Intensive (IC) Consolidation Chemotherapy Cycles on Overall and Relapse Free Survival after Allogeneic Stem Cell Transplant (SCT) in Patients with Acute Myeloid Leukemia (AML) Receiving IC + Venetoclax	Jennifer Marvin-Peek, M.D.
732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster III	
Abstract 4937: HLA-DPB1 Mismatches and the Impact on Unrelated Donor Transplant Outcomes with the Use of Post-Transplant Cyclophosphamide	Portia Smallbone, M.B.B.S.
803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: Poster I	
Abstract 2213: ICASA: An Interactive Comprehensive Atlas of Single Cells in AML from 82 Bone Marrow Samples	Bofei Wang, Ph.D.
902. Health Services and Quality Improvement: Lymphoid Malignancies: Poster I	
Abstract 2282: Developing a Fit-for-Purpose Composite Symptom Score for Representing Symptom Burden for Managing CRS and I cans after CAR T-Cell Therapy	Xin Shelley Wang, M.D.
906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Poster II	
Abstract 3733: Perceptions of Clinical Trials and Factors Influencing Trial Participation Among Hispanic Patients with Non-Hodgkin Lymphoma	Alexis Romero
Abstract 3746: Factors Influencing Clinical Trial Participation Among Patients with Non-Hodgkin Lymphoma Receiving Care in a Safety Net Hospital	Alexis Romero
907. Outcomes Research: Plasma Cell Disorders: Poster I	
Abstract 2411e: Real-World Experience with Isatuximab in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM): Iona-MM Second Interim Analysis	Mahmoud Gaballa, M.D.
907. Outcomes Research: Plasma Cell Disorders: Poster II	
Abstract 3764: Association of Social Determinants of Health Status (SDOH) and Ethnicity with Survival in Multiple Myeloma Patients	Christen Dillard, M.D.
907. Outcomes Research: Plasma Cell Disorders: Poster III	

Abstract 5154: Impact of Ethnicity on Long Term Outcomes of High-Dose Chemotherapy and Upfront Autologous Hematopoietic Stem Cell Transplantation in Patients with Multiple Myeloma	Frances Cervoni Curet, M.D.
908. Outcomes Research: Myeloid Malignancies: Poster I	
Abstract 2434: Adverse Events and Treatment Adjustments Among Newly Diagnosed Patients with Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitors: A Comprehensive Data Analysis of Medicare Fee-for-Service and Commercial Plans in the United States	Elias Jabbour, M.D.
2438: Neighborhood Disadvantage Impacts Outcomes in Patients with Myelodysplastic Syndromes across Different Racial Backgrounds	Mahesh Swaminathan, M.D.
908. Outcomes Research: Myeloid Malignancies: Poster II	
Abstract 3813: Real-World Treatment Patterns and Blood Count Control in Patients with Polycythemia Vera Who Switched from Hydroxyurea to Ruxolitinib	Naveen Pemmaraju, M.D.
Abstract 3816: Ponatinib Safety Profile: An Analysis of 10 Years of Real-World Experience	Elias Jabbour, M.D.
Abstract 3817: Treatment in Clinical Trials Could Potentially Overcome the Disparity in Outcomes of Patients with Acute Myeloid Leukemia from Disadvantaged Neighborhoods	Mahesh Swaminathan, MD
909. Education, Communication, and Workforce: Poster III	
Abstract 5207: Analysis of the Hematology Health Equity Literature: Trends By Topic and Disparity, across Journals, and over Time	James Troyer, M.D.